In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Tirzepatide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 2,165 | 4,766 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 462 (462 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 254 · 162 active47 more mention it but do not test it | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Tirzepatide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 36435581 | 1,117 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Mounjaro says: “Adjunct to diet and exercise for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events”
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
| Body weightMetabolic and weight | 521501182 | 83481717 |
|---|
| Adverse eventsWhole body | 213213 | 50449311 |
|---|
| Gastrointestinal adverse eventsGastrointestinal | 179179 | 185185 |
|---|
| Cardiovascular eventsWhole body | 1551523 | 13313111 |
|---|
| Heart functionCardiovascular | 49427 | 214198142 |
|---|
| LipidsMetabolic and weight | 79763 | 14313733 |
|---|
| Liver fat and liver functionLiver | 5353 | 1361279 |
|---|
| Blood pressureCardiovascular | 5151 | 1201182 |
|---|
| Inflammation markersReproductive and sexual health | 41347 | 117100152 |
|---|
| Kidney functionKidney and urinary | 40391 | 1049932 |
|---|
| Appetite and food intakeMetabolic and weight | 20191 | 1129517 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Tirzepatide differs from Gastric inhibitory polypeptide (GIP) at 11 positions and in 1 end segment.
What is different
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 254 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company13,299 participants29 May 2020 to 12 Jun 2025
Type 2 Diabetes Mellitus
Eli Lilly and Company2,539 participants4 Dec 2019 to 6 Jul 2024
Overweight · Obesity
Eli Lilly and Company2,002 participants20 Nov 2018 to 22 Apr 2021
Type 2 Diabetes Mellitus
47 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Tirzepatide | Liraglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: difference from placebo, in % | −19.4% Difference Dose studied: maximum tolerated dose (10 or 15 mg)52 weeksn = 6702024 | −8.03% mean difference Dose studied: 3.0 mg once daily24 weeksn = 572023 |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | −0.4% HbA1c mean difference Dose studied: 2.5 mg for 4 weeks, 5.0 mg for 8 weeks12 weeksn not reported2026 | −1.09% HbA1c difference Dose studied: 1.8 mg once daily26 weeksn = 344 |
| Heart functionCardiovascularCompared as: value in the arm that got the peptide, in ml | −45 mL Paracardiac adipose tissue change Dose studied: 2.5 mg weekly, increasing to a maximum of 15 mg weekly52 weeksn = 1062025 | −11.5 mL Cardiac adipose tissue change |
| Blood pressureCardiovascularCompared as: difference from placebo, in mm hg | −4.2 mm Hg Net diastolic blood pressure reduction · Shown as a change. The study reports a net diastolic blood pressure reduction of this size. 72 weeksn not reported2024 | 4 mm Hg |
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in % | −19.3% UACR percent change · tirzepatide 5 mg Dose studied: 5 mgweek 40/42n not reported2025 | −40.2% UACR change Dose studied: 1.2-1.8 mg/d |
| SleepSleepCompared as: value in the arm that got the peptide, in events/h | −34.1 to −27.7 events/h AHI change Dose studied: 10 mg or 15 mg (maximum tolerated dose)52 weeksn not reported2026 | −12 events/h Mean difference in AHI |
| Gastrointestinal adverse eventsGastrointestinalCompared as: value in the arm that got the peptide, in % | 42.5% GI adverse events Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026 | 35.7% |
| Adverse eventsMetabolic and weightCompared as: value in the arm that got the peptide, in % | 0.6% Hypoglycemia · tirzepatide 5 mg Dose studied: 5 mg once weekly40 weeksn not reported2021 | 1% Severe hypoglycemia 5.0 years (mean follow-up)n = 5,0472022 |
−19.4%
Difference
Dose studied: maximum tolerated dose (10 or 15 mg)52 weeksn = 6702024
−8.03%
mean difference
Dose studied: 3.0 mg once daily24 weeksn = 572023
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Tirzepatide | Liraglutide |
|---|---|---|
| Cardiovascular eventsCardiovascularCompared as: value in the arm that got the peptide, in % | 23.7% event rate Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026 |
Placebo: −0.01 mL
Dose studied: 1.8 mg/d26 weeksn = 512021
Diastolic nocturnal blood pressure difference
Dose studied: 1.8 mg once daily24 weeksn = 1002017
24 weeksn not reported2024
GI adverse events
Placebo: 17.5%
Dose studied: 1.8 mg once daily26 weeksn = 2792016
−0.4%
HbA1c mean difference
Dose studied: 2.5 mg for 4 weeks, 5.0 mg for 8 weeks12 weeksn not reported2026
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
−45 mL
Paracardiac adipose tissue change
Dose studied: 2.5 mg weekly, increasing to a maximum of 15 mg weekly52 weeksn = 1062025
−11.5 mL
Cardiac adipose tissue change
Placebo: −0.01 mL
Dose studied: 1.8 mg/d26 weeksn = 512021
−4.2 mm Hg
Net diastolic blood pressure reduction · Shown as a change. The study reports a net diastolic blood pressure reduction of this size.
72 weeksn not reported2024
4 mm Hg
Diastolic nocturnal blood pressure difference
Dose studied: 1.8 mg once daily24 weeksn = 1002017
−19.3%
UACR percent change · tirzepatide 5 mg
Dose studied: 5 mgweek 40/42n not reported2025
−40.2%
UACR change
Dose studied: 1.2-1.8 mg/d26 weeks (after 6 weeks of titration)n = 392019
−34.1 to −27.7 events/h
AHI change
Dose studied: 10 mg or 15 mg (maximum tolerated dose)52 weeksn not reported2026
−12 events/h
Mean difference in AHI
24 weeksn not reported2024
42.5%
GI adverse events
Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026
35.7%
GI adverse events
Placebo: 17.5%
Dose studied: 1.8 mg once daily26 weeksn = 2792016
0.6%
Hypoglycemia · tirzepatide 5 mg
Dose studied: 5 mg once weekly40 weeksn not reported2021
1%
Severe hypoglycemia
5.0 years (mean follow-up)n = 5,0472022
No comparable result 74 randomized-trial results measure it in another way or another unit. |
| Metabolic pathways and metabolomicsMetabolic and weightCompared as: value in the arm that got the peptide, in mg/dl | −0.69 mg/dL SUA change · tirzepatide 5 mg Placebo: −0.18 mg/dL Dose studied: 5 mg72 weeksn = 2,5392026 | No comparable result 5 randomized-trial results measure it in another way or another unit. |
|---|
| Quality of lifeWhole bodyCompared as: difference from placebo, in points | No comparable result 38 randomized-trial results measure it in another way or another unit. | 3.4 points IWQOL-Lite estimated treatment difference Dose studied: 3.0 mg3 yearsn = 2,2102018 |
|---|
| Body compositionMetabolic and weightCompared as: difference from placebo, in % | No comparable result 12 randomized-trial results measure it in another way or another unit. | −0.24% Treatment difference Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024 |
|---|
23.7%
event rate
Dose studied: up to 15 mg weeklymedian 46.9 monthsn = 13,1652026
No comparable result
74 randomized-trial results measure it in another way or another unit.
−0.69 mg/dL
SUA change · tirzepatide 5 mg
Placebo: −0.18 mg/dL
Dose studied: 5 mg72 weeksn = 2,5392026
No comparable result
5 randomized-trial results measure it in another way or another unit.
No comparable result
38 randomized-trial results measure it in another way or another unit.
3.4 points
IWQOL-Lite estimated treatment difference
Dose studied: 3.0 mg3 yearsn = 2,2102018
No comparable result
12 randomized-trial results measure it in another way or another unit.
−0.24%
Treatment difference
Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024